Connect with us

Press Release

Domestic Power Generation in the First Half of 2020 Decreased by 8.05% Year-on-Year

Published

on

BEIJING, July 14, 2020 /PRNewswire/ — Huaneng Power International, Inc. (“HPI”, the “Company”) (NYSE: HNP; HKEx: 902; SSE: 600011) today announced its power generation in the first half of 2020.

According to the preliminary statistics of Huaneng Power International, Inc., for the second quarter of 2020, the Company’s total power generation by power plants within China on consolidated basis amounted to 94.949 billion kWh, representing an increase of 3.73% over the same period last year. Total electricity sold by the Company amounted to 91.473 billion kWh, representing an increase of 5.41% over the same period last year. For the first half of 2020, the Company’s total power generation by the power plants within China on consolidated basis amounted to 179.650 billion kWh, representing a decrease of 8.05% over the same period last year. Total electricity sold by the Company amounted to 172.125 billion kWh, representing a decrease of 6.98% over the same period last year. In the first half of 2020, the Company’s average on-grid electricity settlement price for its power plants within China amounted to RMB416.65 per MWh, representing a decrease of 0.68% over the same period last year. In the first half of 2020, the Company’s market based electricity sold amounted to 84.06 billion kwh, with a ratio of 49.89% comparing to the corresponding total electricity sold, representing an increase of 2.84 percentage points over the same period last year.

The decrease in the Company’s power generation was mainly attributable to:

  1. Affected by the epidemic in the first quarter, the national economic growth slowed down, and the Company’s power generation decreased significantly year-on-year;
  2. Since the second quarter, the domestic epidemic situation has been effectively controlled, and the progress of resumption of production in various industries has accelerated. The Company seized the opportunity to actively strive for planned power, and at the same time strengthened power supervision, reduced unit backup, and increased effective generation, realizing a positive year-on-year growth of the Company’s power generation in the second quarter, and narrowing the decline in power in the first quarter.

The power generations (in billion kWh) of the Company, by regions, are listed below:

Region

Power Generation

Electricity Sold

April to June 2020

Change

January to June 2020

Change

April to June 2020

Change

January to June 2020

Change

Heilongjiang Province

3.745

0.27%

6.776

0.84%

3.555

3.53%

6.329

1.83%

Coal-fired

3.422

1.00%

6.135

1.98%

3.214

3.85%

5.703

3.13%

Wind-power

0.286

-7.47%

0.569

-9.85%

0.303

0.63%

0.558

-9.31%

PV

0.037

-1.84%

0.072

-0.63%

0.037

0.31%

0.069

-2.76%

Jilin Province

2.859

1.65%

5.222

4.97%

2.700

1.49%

4.917

4.82%

Coal-fired

2.443

1.37%

4.468

6.03%

2.308

1.60%

4.206

6.31%

Wind-power

0.303

-2.45%

0.567

-3.96%

0.286

-5.69%

0.536

-6.82%

Hydro-power

0.033

64.79%

0.042

55.35%

0.032

66.81%

0.041

56.35%

PV

0.016

-3.75%

0.032

0.38%

0.016

-4.26%

0.032

-0.86%

Biomass power

0.064

15.65%

0.113

1.18%

0.057

16.92%

0.102

1.04%

Liaoning Province

4.058

-6.04%

8.184

-6.53%

3.801

-5.91%

7.597

-6.69%

Coal-fired

3.890

-6.39%

7.866

-6.87%

3.634

-9.86%

7.282

-7.06%

Wind-power

0.109

-5.22%

0.212

2.13%

0.108

-5.58%

0.211

1.94%

Hydro-power

0.012

1147.31%

0.020

40.42%

0.012

1152.77%

0.019

40.58%

PV

0.047

-1.99%

0.086

-1.19%

0.046

-1.74%

0.084

-0.87%

Inner Mongolia

0.059

-10.42%

0.107

-5.71%

0.059

-10.63%

0.106

-5.45%

Wind-power

0.059

-10.42%

0.107

-5.71%

0.059

-10.63%

0.106

-5.45%

Hebei Province

3.086

-6.87%

5.618

-15.96%

2.884

-7.18%

5.238

-16.46%

Coal-fired

2.953

-8.94%

5.346

-18.42%

2.753

-9.38%

4.975

-18.99%

Wind-power

0.118

113.73%

0.242

132.51%

0.116

116.51%

0.234

129.85%

PV

0.016

-1.00%

0.030

7.09%

0.016

-3.43%

0.029

7.68%

Gansu Province

3.371

73.49%

7.339

26.36%

3.212

74.20%

6.988

26.66%

Coal-fired

2.667

90.62%

6.106

27.40%

2.516

91.83%

5.776

27.63%

Wind-power

0.704

29.44%

1.233

21.60%

0.696

30.74%

1.212

22.22%

Ningxia

0.008

15.52%

0.013

5.27%

0.008

15.91%

0.012

8.78%

PV

0.008

15.52%

0.013

5.27%

0.008

15.91%

0.012

8.78%

Beijing

2.038

37.81%

4.098

11.30%

1.987

38.72%

3.900

12.11%

Coal-fired

0.00

0.709

8.03%

0.00

0.625

7.62%

Combined Cycle

2.038

37.81%

3.389

12.01%

1.987

38.72%

3.275

13.01%

Tianjin

1.100

-19.91%

3.052

-4.68%

1.035

-20.12%

2.860

-4.89%

Coal-fired

0.937

-12.56%

2.358

-3.59%

0.876

-12.52%

2.187

-3.85%

Combined Cycle

0.161

-46.22%

0.692

-8.32%

0.157

-46.18%

0.671

-8.15%

PV

0.001

-8.62%

0.002

-17.71%

0.001

-4.18%

0.002

-4.23%

Shanxi Province

1.843

-15.11%

4.617

-11.61%

1.702

-15.26%

4.299

-11.87%

Coal-fired

1.637

-23.54%

3.163

-20.64%

1.499

-24.24%

2.891

-21.26%

Combined Cycle

0.042

596.29%

1.233

3.08%

0.041

560.71%

1.200

3.08%

PV

0.164

584.50%

0.221

426.39%

0.162

582.96%

0.208

395.37%

*Shandong Province

15.811

-24.33%

33.029

-22.67%

16.007

-19.10%

32.868

-18.51%

Coal-fired

15.460

-24.66%

32.402

-22.92%

15.607

-19.62%

32.197

-18.85%

Wind-power

0.229

-7.26%

0.420

-7.66%

0.217

-10.55%

0.404

-8.51%

PV

0.162

26.23%

0.272

24.23%

0.183

42.71%

0.267

22.79%

Henan Province

5.569

16.96%

9.630

-10.79%

5.232

16.86%

9.039

-10.97%

Coal-fired

4.912

10.05%

8.752

-15.52%

4.614

10.04%

8.212

-15.62%

Combined Cycle

0.364

146.22%

0.396

112.97%

0.356

146.74%

0.387

113.37%

Wind-power

0.285

101.93%

0.469

98.56%

0.255

92.67%

0.427

89.19%

PV

0.007

-1.15%

0.013

-2.84%

0.007

-7.32%

0.013

-0.88%

Jiangsu Province

8.872

1.20%

17.008

-12.11%

8.379

0.94%

16.110

-12.16%

Coal-fired

7.304

2.34%

13.903

-15.88%

6.886

2.62%

13.115

-15.81%

Combined Cycle

0.874

-26.24%

1.761

-11.79%

0.857

-26.29%

1.729

-11.80%

Wind-power

0.659

60.78%

1.285

66.69%

0.604

53.01%

1.210

62.08%

PV

0.034

-1.65%

0.058

2.35%

0.033

-3.20%

0.057

0.93%

Shanghai

4.070

21.49%

7.993

-9.46%

3.836

21.40%

7.542

-9.75%

Coal-fired

3.848

29.14%

7.294

-5.83%

3.620

29.31%

6.861

-6.02%

Combined Cycle

0.221

-40.15%

0.699

-35.43%

0.216

-40.11%

0.681

-35.51%

PV

0.00017

0.00017

Chongqing

2.270

-2.68%

4.415

-15.14%

2.111

-2.54%

4.117

-15.05%

Coal-fired

1.905

-3.00%

3.681

-18.45%

1.755

-2.82%

3.402

-18.51%

Combined Cycle

0.305

3.12%

0.625

8.86%

0.297

3.04%

0.609

8.81%

Wind-power

0.060

-17.72%

0.109

-5.03%

0.058

-17.89%

0.106

-5.37%

Zhejiang Province

7.118

22.10%

11.754

-2.32%

6.840

22.29%

11.269

-2.43%

Coal-fired

6.915

21.17%

11.489

-2.81%

6.641

21.35%

11.009

-2.94%

Combined Cycle

0.186

78.73%

0.237

29.72%

0.182

77.85%

0.232

29.63%

PV

0.017

-10.09%

0.028

-3.20%

0.017

-8.19%

0.028

-2.16%

Hubei Province

3.795

-6.45%

7.361

-24.18%

3.557

-6.68%

6.910

-24.41%

Coal-fired

3.560

-6.72%

6.907

-25.81%

3.326

-6.98%

6.466

-26.11%

Wind-power

0.150

-4.82%

0.307

9.15%

0.148

-4.87%

0.302

9.12%

Hydro-power

0.078

3.28%

0.136

26.70%

0.076

2.77%

0.131

26.31%

PV

0.007

12.74%

0.011

11.64%

0.007

9.82%

0.011

11.99%

Hunan Province

2.482

22.75%

4.670

-6.04%

2.324

23.47%

4.361

-6.26%

Coal-fired

2.180

24.30%

4.097

-6.83%

2.026

25.19%

3.802

-6.93%

Wind-power

0.174

30.96%

0.336

3.50%

0.172

30.57%

0.326

1.13%

Hydro-power

0.114

-9.50%

0.215

-9.15%

0.112

-9.75%

0.212

-9.16%

PV

0.014

71.96%

0.021

92.00%

0.013

77.36%

0.021

87.46%

Jiangxi Province

4.708

15.75%

9.001

-2.82%

4.495

15.72%

8.607

-2.90%

Coal-fired

4.416

12.23%

8.489

-5.39%

4.214

12.24%

8.112

-5.46%

Wind-power

0.234

77.40%

0.438

50.97%

0.230

77.82%

0.430

50.74%

PV

0.057

0.075

0.050

0.066

Auhui Province

1.274

-7.48%

2.514

-16.18%

1.212

-7.17%

2.400

-16.13%

Coal-fired

1.184

-6.88%

2.348

-16.40%

1.123

-6.56%

2.235

-16.36%

Wind-power

0.073

5.57%

0.149

4.80%

0.072

6.18%

0.148

4.87%

Hydro-power

0.017

-53.90%

0.017

-65.43%

0.017

-53.43%

0.017

-65.19%

*Fujian Province

3.082

33.07%

5.352

19.60%

3.808

46.40%

6.272

28.74%

*Coal-fired

3.079

33.10%

5.346

19.61%

3.805

46.44%

6.266

28.76%

PV

0.003

15.32%

0.006

17.60%

0.003

11.03%

0.006

16.71%

Guangdong Province

6.856

22.00%

10.231

-3.78%

6.391

19.06%

9.618

-5.49%

Coal-fired

6.640

18.26%

10.011

-5.77%

6.358

18.56%

9.580

-5.78%

Combined Cycle

0.210

0.210

0.027

0.027

PV

0.006

18.33%

0.011

20.63%

0.006

19.95%

0.011

17.68%

Guangxi

0.169

64.16%

0.289

72.06%

0.163

65.51%

0.278

76.05%

Combined Cycle

0.115

57.93%

0.184

53.60%

0.111

60.07%

0.177

54.01%

Wind-power

0.054

79.31%

0.105

122.87%

0.052

78.40%

0.101

134.55%

Yunnan Province

2.951

211.57%

4.618

131.61%

2.727

215.09%

4.262

131.49%

Coal-fired

2.815

252.79%

4.278

169.41%

2.595

259.85%

3.930

171.74%

Wind-power

0.135

-4.43%

0.337

-15.41%

0.131

-3.97%

0.328

-15.27%

Hydro-power

0.001

-93.22%

0.004

-56.18%

0.001

-93.24%

0.003

-56.46%

Guizhou Province

0.077

66.43%

0.166

16.84%

0.075

64.79%

0.157

12.44%

Wind-power

0.051

11.51%

0.134

-5.65%

0.051

11.11%

0.132

-5.51%

PV

0.025

0.032

0.024

0.025

Hainan Province

3.638

-4.91%

6.527

-5.74%

3.376

-4.63%

6.069

-5.52%

Coal-fired

3.503

-5.65%

6.302

-6.66%

3.244

-5.39%

5.849

-6.47%

Combined Cycle

0.074

312.15%

0.107

409.71%

0.0072

303.09%

0.104

418.35%

Wind-power

0.021

16.64%

0.048

3.74%

0.21

15.45%

0.047

3.66%

Hydro-power

0.010

-77.87%

0.018

-67.41%

0.010

-78.36%

0.017

-67.78%

PV

0.030

-1.23%

0.053

3.27%

0.029

-0.08%

0.052

2.92%

Total

94.949

3.73%

179.650

-8.05%

91.473

5.41%

172.125

-6.98%

* According to the requirements of relevant policies, as Huaneng Shandong Bajiao Power Plant & Huaneng Fujian Luoyuan Power Plant (which is owned by the Company) acts as an emergency backup power source, the scope of statistics has not included its coal-fired installed capacity nor its volume of power generation. Since those power plants began to generate power revenue, the Company’s electricity sales in Shandong Province & Fujian Province was greater than the power generation.

For the second quarter of 2020, the power generation of Tuas Power Limited in Singapore, which is wholly-owned by the Company, accounted for a market share of 21.6% in Singapore, representing an increase of 1.6 percentage point compared to the same period of last year. The accumulated power generation for the first half year accounted for a market share of 21.5%, representing an increase of 1.0 percentage point compared to the same period of last year.

In the second quarter of 2020, the controlling generation capacity of the new commissioned units was 1,313.79MW. Thereinto, the newly installed capacity of gas-fired units, wind farms and Photovoltaic were 472.52MW, 357MW and 484.27MW respectively. Besides,the Company completed acquisition of Huaneng Shandong Taifeng New energy Co., Ltd with controlling generation capacity of 100MW and equity-based generation capacity of 65.78MW.

In the second quarter of 2020, the operating life of unit #1 (352 MW) of Huaneng Nantong Power Plant, a subsidiary of the Company, came to an end and the shutdown procedures had been implemented. The installed capacity would no longer be included in the Company’s statistics.

In addition, the installed capacity of some of the power plants in which the Company has equity interests changed in the second quarter of 2020.

Based on the above, as of 30 June 2020, the Company had a controlled generation capacity of 108,111MW and an equity-based generation capacity of 94,878 MW.

~ END ~

About Huaneng Power International, Inc.

Huaneng Power International, Inc. is one of China’s largest listed power producers with controlled generation capacity of 108,111 MW and equity-based generation capacity of 94,878 MW. The power plants of the Company are located in 26 provinces, autonomous regions and municipalities in China. The Company also has a wholly-owned power company in Singapore, and an invested power company in Pakistan.

SOURCE Huaneng Power International, Inc.

This story has been sourced from a third party syndicated feed, agencies. News Galiyara accepts no responsibility or liability for its dependability, trustworthiness, reliability, and data of the text. DigitalGaliyara (OPC) Private Limited management reserves the sole right to alter, delete or remove (without notice). If you have any concerns with the Content, then please write to us at the mail@digitalgaliyara.com Source – PRNewsWire

Press Release

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

Published

on

RedHill Biopharma logo

Positive U.S. Phase 2 safety and efficacy data for opaganib, a leading novel, oral, dual-mechanism drug candidate for moderate-to-severe COVID-19, presented at the World Microbe Forum

Opaganib was associated with a reduction in the need for supplemental oxygen support, earlier time to discharge from hospital and was well tolerated

Opaganib’s global 475-patient Phase 2/3 study is fully enrolled, with study completion expected in the coming weeks

Opaganib is host-targeted and expected to be effective against emerging viral variants

TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

RedHill Biopharma logo

Results and post hoc analyses of data from the 40-patient U.S. Phase 2 study were presented in a poster entitled, “Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia (NCT: 04414618)“[2]. Patients in the study were randomized to receive either opaganib or placebo in addition to standard of care (SoC), predominantly including dexamethasone and/or remdesivir. Findings include:

  • 50% of patients treated with opaganib (n=22) reached room air by Day 14 compared to 22% in the placebo group (n=18). The benefit of reaching room air by Day 14 for patients on opaganib was maintained regardless of whether the patients were receiving dexamethasone and/or remdesivir
  • 86.4% of patients treated with opaganib were discharged from hospital by Day 14 compared to 55.6% of patients treated with placebo
  • Median time to discharge was 6 days for the opaganib group compared to 7.5 days for the placebo group
  • 81.8% of opaganib patients achieved a 2-point improvement in the WHO Ordinal Scale compared to 55.6% of patients in the placebo group – achieved in a median time of 6 days versus 7.5 days, respectively
  • No significant differences in safety-related measures between the two groups (with diarrhea being the main treatment-emergent difference in tolerability)

“The need for an effective oral therapy to treat COVID-19 is clear. Such a therapy would greatly improve our ability to manage this pandemic,” said Kevin Winthrop, MD, MPH, Professor of Infectious Diseases at Oregon Health & Science University, who presented the findings at WMF. “These data, from this proof-of-concept clinical study of opaganib in patients with severe COVID-19, suggest a potential role of SK2 inhibition in combating the effects of this virus. With much more data on opaganib expected in the coming weeks, we could make some real progress toward having access to a much-needed oral therapy for patients who currently have a paucity of options available to them.”

“Presentation of these positive data from our exploratory Phase 2 study support our growing confidence that opaganib could be the first novel, oral therapy to demonstrate efficacy in the treatment of COVID-19 in a large late-stage study. With the recent completion of enrollment of our 475-patient global Phase 2/3 study, we will have a clearer picture of that in the very near future,” said Mark L. Levitt, MD, Ph.D., Medical Director at RedHill. “Opaganib acts on both the cause and effect of COVID-19 via a unique dual antiviral and anti-inflammatory mode of action. Being host-targeted, opaganib is also expected to maintain effect against the emerging SARS-CoV-2 variants, which continue to threaten the progress being made against the pandemic and underscore the urgent need for effective COVID-19 therapeutics.”

The global 475-patient Phase 2/3 study of opaganib in severe COVID-19 has been approved in 10 countries and completed enrollment, through 57 participating sites, on June 6th. The primary endpoint of the study is the proportion of patients breathing room air without oxygen support by Day 14. Additional important outcome measures, such as time to discharge from hospital, improvement according to the World Health Organization Ordinal Scale for Clinical Improvement and incidence of intubation and mortality, will also be captured in the follow-up period of up to 6 weeks. The study received four independent DSMB recommendations to continue following unblinded safety reviews and a futility review. Additionally, an evaluation of the blinded blended intubation and mortality rates to date was encouraging as compared to reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations[3].

About Opaganib (Yeliva®, ABC294640)

Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with dual anti-inflammatory and antiviral activity, that is host-targeted and is therefore expected to be effective against emerging viral variants. Opaganib has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications.

Opaganib is being evaluated as a treatment for COVID-19 pneumonia in a global Phase 2/3 study, which recently completed enrollment, and has demonstrated positive safety and efficacy signals in preliminary top-line data from the 40-patient U.S. Phase 2 study.

Opaganib has also received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer.

Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. Additionally, preclinical in vivo studies have demonstrated opaganib’s potential to ameliorate inflammatory lung disorders, such as pneumonia, and has shown decreased fatality rates from influenza virus infection and ameliorated Pseudomonas aeruginosa-induced lung injury by reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids[4].

The ongoing studies with opaganib are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.   

About RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults[5], Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults[6], and Aemcolo® for the treatment of travelers’ diarrhea in adults[7]. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva®, ABC294640), a firstinclass SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (v) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.         

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include the delay in last patient visit and top-line data from the Phase 2/3 COVID-19 study for opaganib, that the Phase 2/3 COVID-19 study for opaganib may not be successful and, even if successful, such study and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib are likely to be required by regulatory authorities to support such potential applications and the use or marketing of opaganib for COVID-19 patients, that opaganib will not be effective against emerging viral variants, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Movantik®, Talicia® and Aemcolo®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2021. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

 

Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com

Media contacts:

U.S.: Bryan Gibbs, Finn Partners

+1 212 529 2236

bryan.gibbs@finnpartners.com

UK: Amber Fennell, Consilium

+44 (0) 7739 658 783  

fennell@consilium-comms.com

 

[1] Opaganib is an investigational new drug, not available for commercial distribution.

[2] Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia (NCT: 04414618). K. L. Winthrop, A. W. Skolnick, A. M. Rafiq, S. H. Beegle, J. Suszanski, G. Koehne, O.Barnett-Griness, A. Bibliowicz, R. Fathi, P. Anderson, G. Raday, G. Eagle, V. Katz Ben-Yair, H. S. Minkowitz, M. L. Levitt, M. S. Gordon

[3] Based on preliminary blinded blended data from 463 patients. The Company did not conduct a head-to-head comparison study in the same patient population. The theoretical comparison between the global Phase 2/3 study with opaganib and reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations, serves as a general benchmark and should not be construed as a direct and/or applicable comparison as if the Company conducted a head-to-head comparison study.

[4] Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.

[5] Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com.  

[6] Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.       

[7] Full prescribing information for Aemcolo® (rifamycin) is available at: www.Aemcolo.com.

Logo – https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

 

Continue Reading

Press Release

Pandora Boosts Online Sales by Transforming Its Global Omnichannel e-Commerce with IBM Sterling Supply Chain Software

Published

on

Pandora, a leading designer, manufacturer and marketer of hand-finished jewelry, is using IBM Sterling Order Management for improved real-time inventory visibility. Photo courtesy Pandora.

One of the world’s largest jewelry brands by volume uses IBM Sterling Order Management on Cloud to revamp its fulfillment capabilities and customer experience

ARMONK, N.Y., June 21, 2021 /PRNewswire/ — IBM (NYSE: IBM) has worked with Pandora (NASDAQ: PNDORA), a leading designer, manufacturer and marketer of hand-finished jewelry, to help Pandora transform and scale its global omnichannel e-commerce capabilities with IBM Sterling Order Management. Pandora, one of the world’s largest jewelry brands, was able to double its online sales in 2020 and is now leading the jewelry industry with improved real-time inventory visibility to better manage growing demand.

Pandora, a leading designer, manufacturer and marketer of hand-finished jewelry, is using IBM Sterling Order Management for improved real-time inventory visibility. Photo courtesy Pandora.

Pandora’s focus on innovating new customer experiences included using IBM Sterling Order Management to help to increase the company’s supply chain resiliency and business agility, and better mitigate disruptions and risk. By automating more of their order orchestration across channels, they also have opportunity to improve the sustainability and resiliency of their supply chain operations with more efficient delivery.

“Over the past couple of years, Pandora has made significant investments in digital capabilities and data, and we have consolidated, simplified and modernized the technology stack to bring digital and store technology closer together and closer to the customer,” said Jim Cruickshank, VP of Digital Development & Retail Technology, Pandora. “Our mission is about creating a personal experience and we’ve instituted massive platform changes with IBM Sterling and Salesforce to enable new digital-first capabilities that are much more individualized, localized and connected across channels and markets.”

Pandora’s entry into e-commerce over the last six years most recently led them to consolidate legacy technologies while deploying the new order management solution across its key markets. Using IBM Sterling Order Management as its backend for omnichannel fulfillment and Salesforce Commerce Cloud for e-commerce, Pandora created a seamless shopping experience across channels. By automating order orchestration processes, store associates and virtual customer service representatives are able to have an end-to-end view across inventory, order and delivery status to help meet consumer expectations.

To support this ambitious objective, Pandora established a Digital Hub in Copenhagen, Denmark, with dedicated digital, data and tech teams that have played a vital role in the solution’s quick deployment entirely remotely. As the pandemic forced Pandora to temporarily close most of its 2,700 stores, the digital investments in supply chain efficiency helped fuel the company’s e-commerce success. In addition to some of the go-to fulfillment options many retailers offered such as buy online pickup in store (BOPIS) and endless aisle, Pandora also introduced more innovative approaches such as virtual queuing for stores and AR-based virtual trials of products to help drive more immersive customer engagement.

“The global disruption every industry experienced as all forms of commerce were severely impacted by the pandemic was especially challenging for organizations with disconnected distributed order management systems and limited scalability,” said Jordan Speer, Research Manager – Global Supply Chain, IDC Retail Insights. “This vulnerability created a push to more quickly advance technology adoption that helps retailers better respond to fluctuating consumer dynamics. To meet this changing demand, enterprises are looking to harness new tools to achieve increased levels of supply chain resilience and efficiency while also allowing for more virtual interactions.”

Pandora’s detailed view on order and order lines as well as near real-time inventory management helped to improve insights throughout their systems chain spanning warehouse management solutions, e-commerce and customer contact center. This was further enabled with increased automation from self-service capabilities and the use of chatbots aiding customer support functions as Pandora experienced a massive increase in order volumes.

“The lifeblood of the global economy, consumer behavior, has significantly shifted and will continue to evolve with businesses needing to quickly adapt to new preferences and needs. To address this shift, leading retailers like Pandora rely on innovation to increase their business agility by enabling and scaling sustainable supply chain operations using AI and cloud,” said Kareem Yusuf, General Manager, AI Applications and Blockchain, IBM. “Pandora’s experience shows that they can stay competitive as business and technology leaders are finding new ways to create differentiated customer experiences that protect their enterprises from disruptions to help mitigate risk and accelerate growth.”

To hear more about Pandora’s omnichannel experience using IBM Sterling Order Management view their THINK 2021 keynote detailing how they continue to execute on their strategic initiatives by navigating one of the world’s greatest supply chain disruption.

About Pandora

Pandora designs, manufactures and markets hand-finished jewelry made from high-quality materials at affordable prices. Pandora jewellery is sold in more than 100 countries through more than 6,700 points of sale, including around 2,700 concept stores.

Headquartered in Copenhagen, Denmark, Pandora employs 26,000 people worldwide and crafts its jewelry at two LEED certified facilities in Thailand using mainly recycled silver and gold. The company plans to be carbon neutral by 2025 and has joined the Science Based Targets initiative to reduce emissions across its full value chain. Pandora is listed on the Nasdaq Copenhagen stock exchange and generated sales of DKK 19.0 billion (EUR 2.5 billion) in 2020.

About IBM Sterling Supply Chain

IBM Sterling Supply Chain solutions empower IT and supply chain professionals with greater visibility, transparency and trust to proactively predict and mitigate disruption, improve B2B information flow, and optimize inventory utilization and fulfillment. Learn how our AI- and blockchain-enabled solutions help you build an intelligent, self-correcting supply chain at www.ibm.com/supply-chain.

Contacts:

Heli Koenkyto

Heli.Koenkyto@ibm.com

Erik Mason

erik.mason@ibm.com

IBM Corporation logo.

Photo – https://mma.prnewswire.com/media/1536971/IBM_Sterling_Pandora_mobile.jpg

Logo – https://mma.prnewswire.com/media/95470/ibm_logo.jpg

Continue Reading

Press Release

Xinhua Silk Road: 2021 World Industrial and Energy Internet Expo & International Industrial Equipment Exhibition held on Fri. in E. China's Changzhou

Published

on

Photo: The 2021 World Industrial and Energy Internet Expo and International Industrial Equipment Exhibition kicks off on Friday, in Changzhou, east China's Jiangsu Province.

BEIJING, June 21, 2021 /PRNewswire/ — The 2021 World Industrial and Energy Internet Expo and International Industrial Equipment Exhibition kicked off on Friday, in Changzhou, east China’s Jiangsu Province.

Photo: The 2021 World Industrial and Energy Internet Expo and International Industrial Equipment Exhibition kicks off on Friday, in Changzhou, east China's Jiangsu Province.

Hundreds of experts, scholars and industry elites actively participated in the event to discuss together hot topics such as industrial Internet, energy Internet, smart manufacturing, big data, etc., and share their cutting-edge views and experiences with an aim to inject new impetus into the country’s low-carbon manufacturing industry.

It is learned that agreements on 20 key projects were signed at this year’s expo with a total investment of 30 billion yuan.

Those projects cover fields such as high-end equipment manufacturing, power batteries, 5G communications, photovoltaic new energy, industrial Internet, etc.

The event has been held for three consecutive years since 2019 and achieved remarkable results. 

It is learned that as the only exhibition in Jiangsu that takes the industrial Internet as the local strength and characteristic industry, the expo adheres to the digital transformation of the service industry. The expo has intensively displayed a batch of the latest technologies and achievements in the fields of industrial and energy Internet and high-end equipment manufacturing sectors, accelerated the gathering of various high-end factors such as industry technology, talents, project industries, etc., and played a positive role in the development of the industrial Internet in Jiangsu and even the whole country.

At present, Changzhou is steering towards its positioning of “international intelligent manufacturing city and the central axis hub of the Yangtze River Delta “, firmly grasping the trend of the industrial Internet, vigorously developing intelligent manufacturing and smart energy, and constantly polishing the golden sign of Changzhou’s intelligent manufacturing.

Original link: https://en.imsilkroad.com/p/322222.html

Photo – https://mma.prnewswire.com/media/1537420/2021_World_Industrial_and_Energy_Internet_Expo.jpg  

Continue Reading

Trending